Latest Headlines

  1. AlphaMeld Corporation And VedTechBio Forge Strategic AI-Powered Drug Discovery Alliance To Transform Metabolic And Liver Disease Therapeutics 6/10/2025

    AlphaMeld Corporation, a global frontrunner in AI-powered drug discovery, and VedTechBio Research Pvt. Ltd., an emerging biopharma technology innovator specializing in translational research and program execution, today announced a multi-program strategic partnership to accelerate the development of novel therapies for metabolic and liver diseases, including obesity and rare hepatic disorders.

  2. CN Bio Introduces Cross-Species DILI Services To Enhance In Vitro To In Vivo Extrapolation During Preclinical Drug Development 6/10/2025

    CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, has introduced two new animal microphysiological system (MPS) models that enhance translatability in preclinical drug safety and toxicology assessments to its Contract Research Services (CRS).

  3. Bexorg Announces Research Collaboration With Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform To Enhance CNS Drug Development 6/10/2025

    Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, today announced a multi-program research collaboration with Biohaven Ltd. (NYSE: BHVN) to identify, de-risk, and advance next-generation therapies for CNS disorders.

  4. IonQ Speeds Quantum-Accelerated Drug Development Application With AstraZeneca, AWS, And NVIDIA 6/9/2025

    IonQ, a leading commercial quantum computing and networking company, announced results of a collaborative research program between IonQ, AstraZeneca, Amazon Web Services (AWS), and NVIDIA to develop and demonstrate a quantum-accelerated computational chemistry workflow which has the potential to power world-changing innovation in healthcare, life sciences, chemistry, and more.

  5. MIT Releases Breakthrough Protein-Binding Affinity Model, Expanding Role Of AI In Drug Discovery 6/6/2025

    Understanding how molecules interact is central to biology: from decoding how living organisms function to uncovering disease mechanisms and developing life-saving drugs. In recent years, models like AlphaFold changed our ability to predict the 3D structure of proteins, offering crucial insights into molecular shape and interaction.

  6. Juvenescence Acquires AI Drug Discovery Company Ro5 To Boost R&D Capabilities And Drive Pipeline Of Medicines To Extend Healthy Lifespan 6/5/2025

    Juvenescence Limited, a clinical stage AI-enabled biotech company, is pleased to announce the acquisition of Ro5 Inc., a proprietary AI drug discovery company.

  7. Mission Bio Unveils Industry-First Single-Cell Genotype And Targeted Gene Expression Solution Aimed At Derisking Cancer Drug Clinical Development 6/5/2025

    Mission Bio, a leader in single-cell multi-omics solutions for precision medicine, today announced the launch of its Single-Cell Genotype and Targeted Gene Expression assay, expanding the capabilities of its Tapestri Platform to become the only commercial solution that delivers simultaneous genotype and targeted gene expression profiling from over 10,000 single cells.

  8. Molecular Health And Axxam Enter Into A Strategic Partnership To Bolster The Discovery Of Innovative Targets In Drug Development 6/4/2025

    Axxam S.p.A., a premier provider of integrated early discovery services, and Molecular Health GmbH, a leader in artificial intelligence (AI)-driven development solutions, are announcing a strategic collaboration to accelerate the identification and validation of novel therapeutic targets across a broad range of therapeutic areas.

  9. New NIST Standard Helps Deliver The Right Dosage Of Cancer-Fighting Drugs 6/3/2025

    Scientists at the National Institute of Standards and Technology (NIST) have developed the first U.S. standard for measuring the radioactivity of actinium-225, a radioactive isotope that drug companies are using to develop a new class of anticancer drugs.

  10. Technology Developed By ANBM To Be Utilized For New Drug Discovery Program 6/3/2025

    Furthering the University of Arizona College of Medicine – Phoenix’s research mission to cultivate research both locally and globally, the Center for Applied NanoBioscience and Medicine (ANBM) has agreed to a technology development program and commercialization partnership with Mitsubishi Gas Chemical Company (MGC), Inc.